SupremeCourt

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Saturday, March 2, 2013

Patents vs. Patients: Department of Pharmaceuticals issues draft policy on pricing of patented drugs

Posted on 7:57 PM by Unknown
Earlier this week, the Department of pharmaceuticals (DOP) issued a draft proposal on price negotiation of patented drugs and has invited comments from stakeholders on the recommendations of the committee before the end of this month. This draft policy proposal couldn't have come at a better time, especially since the IPAB decision on Bayer’s appeal against compulsory license(CL) issued for its Nexavar (First ever post TRIPS CL granted by India) is expected early next week. 


The Parliamentary standing committee’s report in May 2012 noted that no action had been taken on gamut of issues concerning availability of quality medicines at affordable prices. This report acted as a catalyst for the DOP committee which was set up in 2007, to come up with the proposal on pricing system for patented drugs. 

Image from here

The committee noted that the three categories of patented drugs viz. (1) A totally new class of drugs which have no therapeutic equivalence (2) A drug that has therapeutic equivalence in addition to improved therapeutic equivalence over the existing drug (“improved efficacy”) (3) A drug which has comparable therapeutic efficacy as an existing drug, should be given differential treatment while fixing the price. 


The report stated that the prices for patented drugs are high and beyond the reach of general masses of India even after factoring in Gross National Income (GNI) and purchasing power parity (PPP). For instance after price is weighted in terms of per capita GNI, If Sunitinib (25mg capsule) costs Rs 23,462 in India its cost in France and Australia would be Rs.17,541 and Rs.13,430 respectively. 

The proposal stated that the Government should expand the coverage of Health insurance. Currently, Health insurance coverage by Govt. and other private operators is around 23% and majority of population spend money from their own pockets for medicare expenses. In addition the committee recommended price negotiation methodology for procurement of patented medicines by Govt. and health insurance companies. 

The committee observed that “Once a Government appointed Committee goes for some form of price regulation of patented medicines and fixes a price of the medicines which is accepted by the government, this fixed price would be supposed to be reasonable and hence it won’t be possible for the Government to use the tool of Compulsory License on the ground of reasonableness of the price of the patented medicine” 

Although this would undermine CL provisions, compulsory license could still be granted if any one of the other criteria is met i.e. “reasonable requirements of the public have not been satisfied” or “invention was not worked in the territory of India.” 

Also, as reported here Sakthivel Selvaraj, a public health activist with the All India Drug Action Network (AIDAN) opines “If the prices have to be decided by way of negotiations, why should the government get involved at all. Hospitals can individually negotiate prices when they purchase in bulk and get up to 20% discounts. Besides when the government starts fixing the prices, cases for compulsory licensing will also get weaker.” 

AIDAN supported by several NGOs had filed a PIL in the Supreme Court in 2003 (almost a decade ago) seeking Govt. intervention to keep the prices of essential drugs within the reach of common man.The PIL had come up for hearing several times and in the last hearing AIDAN’s counsel expressed apprehension that National Pharmaceuticals Pricing Policy drafted in 2011,may lead to a steep increase in drug prices. No one has heard about the PIL since then. 

With the Govt. deliberating the issue of CL licenses for 3 more anticancer drugs this proposal on pricing of patented drugs could have a huge impact. 

While we are on the topic of pricing, Shamnad’s thought provoking article on pharmaceutical pricing is an excellent read. 


Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in access, Indian Pharma, Madhulika, Price Control | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • IPAB on Payyannur Ring
    [*S lightly long post] Background: The Intellectual Property Appellate Board (“ IPAB ”), in its recent order in SubhashJewellery v. Payyan...
  • Guest Post: Intermediary liability in defamation cases - Parle, Mouthshut & Visakha cases to clarify the law
    Chaitanya Ramachandran, who has blogged for us previously over here and here , has sent us this excellent guest post analyzing the extent of...
  • IP Research Assistant position at IIT, Madras
    Feroz Ali Khader, MHRD IP Chair at the Indian Institute of Technology (IIT) Madras, is looking for research assistants to work on various is...
  • Dorling Kindersley v. Sanguine Technical Publishers
    A recent Delhi High Court order passed on 21 January, 2013  with respect to copyright licensing has come to our notice. An analysis of the j...
  • Call for Papers: IIT Bombay and MHRD jointly announce the 2nd International Conference on Management of Intellectual Property and Strategy
    The readers may be interested to know that the Shailesh J. Mehta School of Management of IIT Bombay is geared up to host, in collaboration w...
  • SpicyIP Tidbit: ALCS August Distribution
    In the UK, the Authors' Licensing and Collecting Society is an organization run and owned by writers that collects money due to its mem...
  • Delhi HC rejects the "Hot News" Doctrine: A Summary
    The applicability of the Hot News doctrine was rejected recently in a landmark ruling delivered by Justice Bhat of the Delhi HC. This post i...
  • Satyajit Ray's sketches and copyright controversies
    A copyright row appears to have started between the Satyajit Ray Society and the Delhi Art Gallery, that is organising a countrywide exhibit...
  • Thalappakatti biryani trademark row
    The southern district of Dindigal in Tamil Nadu occupies a special place in the hearts of biryani lovers. In the late 1950s, one Nagasamy N...
  • Karnataka High Court temporarily restrains German company from exploiting trade secrets of Homag India
    Image from here In an interesting judgment dated 10th October, 2012 the Karnataka High Court, sitting at Bangalore, has passed an interim in...

Categories

  • 126 (1)
  • 3(d) (4)
  • 3(f) (1)
  • 3(i) (1)
  • 3(k) (2)
  • Academic Writing (1)
  • access (10)
  • access to food (1)
  • access to health (3)
  • AIA (1)
  • AIDS/HIV (3)
  • Antitrust (2)
  • Bajaj v LML (1)
  • Basmati Row (2)
  • Biological Diversity (5)
  • Biologics (2)
  • biopiracy (4)
  • biotech (7)
  • Bollywood (25)
  • Broadcasters Rights (5)
  • Budget (1)
  • business method patent (2)
  • Call for papers (2)
  • Cipla (2)
  • Comparative Advertising (4)
  • Competition law (8)
  • Compulsory Licensing (27)
  • condonation of delay (1)
  • Conference (4)
  • Constitution (12)
  • Contracts (1)
  • Controller's decisions (8)
  • Copyright (112)
  • Copyright Amendment Bill 2010 (23)
  • copyright board (4)
  • Copyright Exceptions (6)
  • copyright office (1)
  • Copyright Rules (2013) (5)
  • Copyright Societies (9)
  • Counterfeiting (1)
  • creativity (1)
  • Cross Retaliation (1)
  • csir (4)
  • d (1)
  • D.U. Photocopy Case (16)
  • Darjeeling Tea (3)
  • Data Exclusivity (2)
  • Database (1)
  • DCGI (2)
  • decompilation (2)
  • defamation (9)
  • Designs (3)
  • Designs Act (3)
  • Differential Pricing (2)
  • Dilution (1)
  • Disabilities (3)
  • Disability (2)
  • DMCA (2)
  • Doha Declaration (1)
  • Domain Names (2)
  • Draft Policy of the Indian Government (2)
  • DRM (1)
  • Drug Regulation (7)
  • education (12)
  • Enercon (1)
  • Enforcement (1)
  • EU (2)
  • ex parte (2)
  • exhaustion (3)
  • Exhaustion of Rights (2)
  • Fair Dealing (8)
  • Fair Use (11)
  • Federal Circuit (1)
  • Fees (3)
  • FICCI (7)
  • FRAND (2)
  • free trade agreement (3)
  • FTA (3)
  • G.I. Registry (4)
  • gene sequences (3)
  • Generic medicine (4)
  • Geographical Indication (14)
  • Gilead (1)
  • Glenmark (5)
  • Gopika (34)
  • Guest post (11)
  • guidelines (1)
  • GWU-CII (1)
  • Herceptin (1)
  • hot news (3)
  • ICANN (1)
  • incremental innovation (1)
  • independence (1)
  • india (5)
  • Indian Government (1)
  • Indian patent litigation (27)
  • Indian Pharma (35)
  • Injunction (10)
  • Innovation (7)
  • INTA (1)
  • Intermediaries (10)
  • internet (11)
  • Internet Access Providers (IAPs) (5)
  • Internet Censorship (7)
  • IP scholarship (3)
  • IP aware (4)
  • IP Course (3)
  • IP Education (1)
  • IP Policy (11)
  • IP update (4)
  • ip writing competition (1)
  • IPAB (34)
  • ipchair (1)
  • IPO (1)
  • IPRS (5)
  • IT Act (1)
  • Journal (2)
  • judicial independence (3)
  • Jurisdiction (1)
  • Kruttika (4)
  • Legal Education (3)
  • Legal Research Tools (1)
  • Legal Scholarship (2)
  • library (2)
  • Licensing (7)
  • Madhulika (20)
  • mathematical methods (1)
  • Media law (3)
  • medical method (1)
  • Merck (4)
  • mhrd ip chair (1)
  • Microsoft (3)
  • Middle Path (1)
  • Moral Rights (2)
  • Movies (18)
  • musical work (2)
  • nanotechnology (1)
  • Natco (3)
  • natco defamation suit (5)
  • natco vs bayer (4)
  • need for transparency (1)
  • Novartis (8)
  • Novartis patent case in India (11)
  • NPEs (2)
  • nujs (1)
  • NUJS Conference (2)
  • Obituary (1)
  • obviousness (7)
  • Off-Topic (2)
  • online course (4)
  • Open Access (6)
  • Open Source (2)
  • Opposition (3)
  • Parallel Imports (4)
  • Parliament (1)
  • passing off (5)
  • Patent (52)
  • Patent act (10)
  • patent agent (5)
  • patent agent exam (9)
  • patent agent exam qualifications (3)
  • patent infringement (5)
  • Patent Licensing (2)
  • Patent litigation (2)
  • Patent Office (19)
  • patent pool (3)
  • Patent Prosecution (7)
  • Patent rules (2)
  • Patent Strategies (8)
  • Patents (9)
  • pegasus (1)
  • Personality Rights (1)
  • Pfizer (1)
  • Pharma (18)
  • Piracy (5)
  • plagiarism (3)
  • Plant Variety Protection (2)
  • post grant (1)
  • Prashant (2)
  • Preventive Detention (1)
  • Price Control (6)
  • prior publication (1)
  • Privacy (3)
  • Prizes (1)
  • public health (3)
  • Public Interest (4)
  • Publicity Rights (4)
  • Publishing (3)
  • radio (2)
  • Rajiv (18)
  • Rectification Petition (2)
  • Rejection (1)
  • research (3)
  • reverse engineering (2)
  • revocation (4)
  • rip (1)
  • Roche (2)
  • Roche vs Cipla (1)
  • Royalty (2)
  • RTI (2)
  • Scholarship (4)
  • section 16 (1)
  • Section 3(d) (7)
  • section 8 (6)
  • shamnad (11)
  • Shan Kohli (4)
  • Shouvik Kumar Guha (30)
  • Smartphones/Tablets (2)
  • Social Innovation (1)
  • Software (10)
  • software enforcement (3)
  • software patent (3)
  • Special 301 Report (1)
  • Spicy Tidbits (6)
  • spicyip (1)
  • SpicyIP Accolades (1)
  • SpicyIP Announcements (9)
  • SpicyIP Case (1)
  • SpicyIP Cases (3)
  • spicyip commiseration (1)
  • SpicyIP Events (11)
  • SpicyIP Fellowship (5)
  • SpicyIP Guest Series (22)
  • SpicyIP Interview (2)
  • SpicyIP Jobs (4)
  • SpicyIP Jobs/General (2)
  • SpicyIP Review (1)
  • SpicyIP Tidbits (11)
  • SpicyIP Weekly Review (27)
  • Statutory Licensing (1)
  • STI Policy 2013 (4)
  • Sugen (3)
  • Supreme Court of India (5)
  • Swaraj (19)
  • Tarnishment (1)
  • Technology (6)
  • Technology Transfer (5)
  • TKDL (5)
  • TPP (1)
  • trade (4)
  • Trade Secret Protection (1)
  • Trademark (59)
  • Trademark dilution (1)
  • Trademark Registry (9)
  • Traditional Knowledge (7)
  • Transparency (5)
  • treaty (1)
  • trial (1)
  • tribunals (2)
  • TRIPS (11)
  • UK (3)
  • unfair competition (5)
  • UNFCCC (1)
  • Universities Research and Innovation Bill (2)
  • US (1)
  • US Patent Reform (1)
  • US Supreme Court (3)
  • viva (3)
  • WIPO (5)
  • Working a Patent (2)
  • Workshop (4)
  • writ (1)
  • WTO (1)

Blog Archive

  • ▼  2013 (364)
    • ►  September (13)
    • ►  August (41)
    • ►  July (36)
    • ►  June (36)
    • ►  May (32)
    • ►  April (51)
    • ▼  March (66)
      • US Department of Justice conducts review of IPXI
      • Public health activists lose challenge against Gil...
      • Bombay HC restrains the release of any trailers/te...
      • SpicyIP Tidbit: Viacom restrained from using 'Naut...
      • Recent decision on Protection of Plant Varieties A...
      • Ericsson sues Micromax over SEPs in 100-crore Pate...
      • Full Bench Delhi HC (Design Act)- Reckitt Benkise...
      • Guest Post: U.S. Supreme Court hears arguments in ...
      • Patent Office publishes final version of Guideline...
      • Joint Committees related to Trademark Matters
      • SpicyIP Weekly Review (March- Week 4)
      • Copyright Constitutionality Challenges
      • Statistics of patent grants in India
      • Breaking News: India's Copyright Amendments Challe...
      • Copyright Rules, 2013 designed to fail the Copyrig...
      • Copy of the Copyright Rules, 2013
      • 'Mad Men' controversy
      • A clarification on the Fox-‘Knockout’ copyright di...
      • The recent AMUL-IMUL trademark controversy
      • India’s patent policy: Big Pharma’s grouse?
      • Pratibha Syntex lawsuit still pending before the D...
      • SpicyIP Tidbit: An IP Thriller from an IP lawyer
      • US Supreme Court Supports Parallel Imports: Lesson...
      • IPAB’s first CL decision, resounding emphasis on p...
      • Government notifies Copyright Rules, 2013
      • SpicyIP Weekly Review (March Week 3)
      • Knock(ed) Out!
      • US Patent Reform - 2013: A brief look at the AIA
      • Breaking News: Second Compulsory Licensing Applica...
      • Zanjeer Remake Row before the Bombay HC
      • Guest Post: Kallam Anji Reddy: 1941 - 2013
      • EU Human Rights Court justifies The Pirate Bay con...
      • Breaking Hot News: Madras High Court strikes down ...
      • DU Photocopy Case: Academicians and Authors expres...
      • Bombay HC: Publication of Examination Report on we...
      • Breaking "Hot" News: A "Star" Win for Unfair Compe...
      • The role played by Microsoft in getting California...
      • An outrageous Californian attempt at extra-territo...
      • Standing Committee Report on ‘The Universities Res...
      • Standing Committee Report on ‘The Universities Res...
      • Spicy IP Weekly Review: March 2nd Week
      • Latest update from Campaign for affordable trastuz...
      • A recent study shows that U.S. firms don’t actuall...
      • A Tantalising Copyright Offer: Lessons from Canada...
      • Auditing the worldwide litigation involving ‘Basma...
      • ‘Rethinking the data exclusivity debate in India’ ...
      • UOI v. Malhotra Book Depot- restoration of trademark.
      • Call for Papers: IIT Bombay and MHRD jointly annou...
      • Guest Post: Eye witness account of India's first c...
      • Guest Post: Eye witness account of India's first c...
      • Bombay High Court – Are courts allowed to examine ...
      • Life of P.I. - Keynote address by Justice Prabha S...
      • SpicyIP Event: Announcing Expert Speaker Panel for...
      • SpicyIP Tidbit: Saregama loses copyright claim for...
      • Guest Post: Book Review - V.J. Taraporevala, Law o...
      • Blocking order issued against six UK ISP's by Engl...
      • Film release strategies and anti-competitive pract...
      • Compulsory Licensing is Not a Bad Word!
      • ‘First set up the labs, then dream the Nobel’
      • Spicy IP Weekly review (March Week 1)
      • December 2012: Controller's decisions at the IPO
      • Patents vs. Patients: Department of Pharmaceutical...
      • SpicyIP Tidbit: ViiV Healthcare collaborates with ...
      • Breaking News: Student Association Impleaded in Ac...
      • Kerala State Central Library digitizes Rare Books ...
      • Bombay High Court Decision on Trademark Infringeme...
    • ►  February (40)
    • ►  January (49)
  • ►  2012 (131)
    • ►  December (29)
    • ►  November (42)
    • ►  October (50)
    • ►  September (10)
Powered by Blogger.